Zelira Therapeutics launches HOPE™ range of autism spectrum disorder products in Washington DC

Zelira Therapeutics Ltd (ASX:ZLD) (OTCMKTS:ZLDAF) has launched its HOPE™ range of autism spectrum disorder products in Washington DC through its partnership with Alternative Solutions LLC, a licensed manufacturer and distributor of medical cannabis products. Washington DC has reciprocity with 32 other states in the USA with approved medical cannabis programs. This expands access for Zelira’s HOPE™ range of products to patients registered in all the 32 States, as they can legally purchase medical cannabis products at an approved dispensary in Washington DC. The company will receive a licensing fee and ongoing royalties on sales of HOPE™ within this territory. “Huge step forward” Zelira Therapeutics managing director Dr Oludare Odumosu said: “The successful launch of HOPE in Washington DC is a huge step forward in Zelira’s strategic focus on expanding access to HOPE™ throughout the USA. “We look forward to partnering with alternative solutions to support the growth of our product in these new markets.” Shares have been more than 15% higher intra-day to A$0.061. Customer uptake and sales trajectories HOPE™ is now available at the National Holistic Healing Center, a medical cannabis dispensary near Dupont Circle, whose dedicated team assists patients in treating their symptoms through ailment-strain alignment. With the gradual relaxation of COVID restrictions, Zelira remains focused on further expanding the distribution of HOPE™ through licensing agreements in each approved market across the US. The experience of HOPE™ products in its launch state of Pennsylvania provides Zelira with confidence that customer uptake and sales trajectories will be similar in Washington DC and other markets. Alternative Solutions CEO Matt Lawson-Baker said: “We are thrilled to partner with Zelira in bringing HOPE™ to Washington DC and look forward to bringing patients scientifically formulated medicines they can trust.” About Zelira Zelira is a leading global therapeutic medical cannabis company with access to the world’s largest and fastest-growing cannabis markets. The company owns a portfolio of proprietary revenue-generating products and a pipeline of candidates undergoing clinical development that are positioned to enter global markets. It has two proprietary formulations under the HOPE™ brand that are generating revenues in Australia, Pennsylvania and have been licensed in Louisiana and Washington DC with other states in the US expected to follow.